Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Sex Transm Dis ; 36(6): 395-9, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19556934

ABSTRACT

BACKGROUND: Little is known about the direct medical cost and overall burden of trichomoniasis among women in the United States. METHODS: We extracted insurance claims for trichomoniasis for 2001 to 2005 from the MEDSTAT MarketScan database using International Classification of Diseases, ninth revision codes. The analysis was restricted to outpatient care and prescription drug claims for women in 4 age categories; under 15, 15 to 24, 25 to 34, and 35 to 64. We used Current Procedures Terminology codes to analyze diagnostic methodologies. All costs were adjusted to 2005 US dollars. RESULTS: The average outpatient and prescription drug costs per episode for all ages were 97 dollars and 9 dollars, respectively. The resulting average total cost per episode was 101 dollars (about 50% did not have drug costs). Average total cost among women aged 15 to 24 years (120 dollars) was significantly (P < 0.01) higher than all other age categories. The estimated annual economic burden was 6.8 million dollars among privately insured women and 18.9 million dollars among all women from the United States. The incidence rate for female enrollees (all ages) having claims was 91 per 100,000 enrollees. Incidence rates were highest for women aged 25 to 29 years (185 per 100,000), followed by women aged 20 to 24 years (166 per 100,000). The most common diagnostic procedure seemed to be wet mount, but nonspecificity of Current Procedures Terminology codes inhibited the analysis of diagnostic methodologies. CONCLUSION: The estimated economic burden was highest among reproductive age women (15-34 years). Our estimated economic burden represents a lower-bound estimate because it was based on direct medical costs only.


Subject(s)
Ambulatory Care/economics , Antitrichomonal Agents/economics , Health Care Costs , Trichomonas Infections/drug therapy , Trichomonas Infections/economics , Adolescent , Adult , Antitrichomonal Agents/therapeutic use , Costs and Cost Analysis , Drug Costs , Employer Health Costs , Female , Humans , Incidence , Middle Aged , Trichomonas Infections/epidemiology , United States/epidemiology , Young Adult
2.
Dig Liver Dis ; 36(5): 322-6, 2004 May.
Article in English | MEDLINE | ID: mdl-15191200

ABSTRACT

BACKGROUND AND AIM: One-week triple therapy for Helicobacter pylori revealed, during these last few years, a decrease in the eradication rate, so that the prolongation of its duration has been proposed. A sequential scheme recently showed very satisfactory results. We performed a prospective randomised study with the aim of either evaluating whether the triple therapy prolongation may improve its effectiveness and comparing its outcome with that of sequential regimen. PATIENTS AND METHODS: Three hundred and forty-two H. pylori positive patients completed the study. They were randomised to receive one of the following treatments: (i) a 7-day triple therapy comprising of rabeprazole (20 mg, b.i.d.) plus clarithromycin (500 mg, b.i.d.) and amoxycillin (1 g, b.i.d.); (ii) a 10-day triple therapy comprising the same scheme; (iii) a 10-day sequential regimen comprising of rabeprazole (20 mg, b.i.d.) plus amoxycillin (1 g, b.i.d.) for 5 days followed by rabeprazole (20 mg, b.i.d.) plus clarithromycin (500 mg, b.i.d.) and tinidazole (500 mg, b.i.d.) for the next 5 days. Therapeutic results were expressed using both intention-to-treat and per protocol analyses with 95% confidence intervals. A model of multivariate logistic regression analysis was performed using therapeutic outcome as a dependent variable and including endoscopic finding, smoking habit, age and sex as candidates for the model. RESULTS: Sequential regimen showed a significant gain in the eradication rate as compared to the 7-day (P < 0.0001) and the 10-day (P < 0.01) triple therapies, respectively. Overall eradication was lower in smokers than in non-smokers, but the difference remained significant only in the 7-day triple therapy (P < 0.01). Additionally, the overall eradication was higher in peptic ulcer than dyspepsia (P < 0.01), even if this difference was significant only for both triple therapies. CONCLUSIONS: Seven-day triple therapy achieves disappointing eradication rates in dyspeptics and smokers. Prolonging triple therapy to 10 days does not significantly improve the eradication rate. The novel 10-day sequential regimen is more effective and equally tolerated than the 10-day triple therapy.


Subject(s)
Helicobacter Infections/drug therapy , 2-Pyridinylmethylsulfinylbenzimidazoles , Amoxicillin/administration & dosage , Amoxicillin/adverse effects , Amoxicillin/economics , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/economics , Anti-Ulcer Agents/administration & dosage , Anti-Ulcer Agents/adverse effects , Anti-Ulcer Agents/economics , Antitrichomonal Agents/administration & dosage , Antitrichomonal Agents/adverse effects , Antitrichomonal Agents/economics , Benzimidazoles/administration & dosage , Benzimidazoles/adverse effects , Benzimidazoles/economics , Clarithromycin/administration & dosage , Clarithromycin/adverse effects , Clarithromycin/economics , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Therapy, Combination , Dyspepsia/drug therapy , Dyspepsia/microbiology , Female , Helicobacter Infections/complications , Helicobacter pylori , Humans , Male , Middle Aged , Multivariate Analysis , Omeprazole/analogs & derivatives , Patient Compliance , Peptic Ulcer/drug therapy , Peptic Ulcer/microbiology , Prospective Studies , Rabeprazole , Smoking/epidemiology , Tinidazole/administration & dosage , Tinidazole/adverse effects , Tinidazole/economics , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...